 Arvinas Inc NASDAQ: ARVN and Pfizer Inc NYSE: PFE have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC PROteolysis TArgeting Chimera estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. 